1,072
Views
30
CrossRef citations to date
0
Altmetric
Drug Evaluation

Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development

ORCID Icon, , & ORCID Icon
Pages 565-578 | Received 03 Dec 2019, Accepted 06 Mar 2020, Published online: 25 Mar 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Cristina Martinez-Fernandez de la Camara, Jasmina Cehajic-Kapetanovic & Robert E. MacLaren. (2022) Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa. Expert Opinion on Emerging Drugs 27:4, pages 431-443.
Read now

Articles from other publishers (29)

Jayanth Venkatarama Reddy, Katherine Raudenbush, Eleftherios Terry Papoutsakis & Marianthi Ierapetritou. (2023) Cell-culture process optimization via model-based predictions of metabolism and protein glycosylation. Biotechnology Advances 67, pages 108179.
Crossref
Helia Ashourizadeh, Maryam Fakhri, Kiana Hassanpour, Ali Masoudi, Sattar Jalali, Danial Roshandel & Fred K. Chen. (2023) Pearls and Pitfalls of Adaptive Optics Ophthalmoscopy in Inherited Retinal Diseases. Diagnostics 13:14, pages 2413.
Crossref
Alan R. Abraham, Panayiotis Maghsoudlou, David A. Copland, Lindsay B. Nicholson & Andrew D. Dick. (2023) CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions. Frontiers in Ophthalmology 3.
Crossref
Reza Ladha, Thijs Meenink, Jorrit Smit & Marc D. de Smet. (2021) Advantages of robotic assistance over a manual approach in simulated subretinal injections and its relevance for gene therapy. Gene Therapy 30:3-4, pages 264-270.
Crossref
Fan Jiang, Tiehui Sun, Peng Cheng, Jie Wang & Wenping Gong. (2023) A Summary on Tuberculosis Vaccine Development—Where to Go?. Journal of Personalized Medicine 13:3, pages 408.
Crossref
Leopold Schmetterer, Hendrik Scholl, Gerhard Garhöfer, Lucas Janeschitz-Kriegl, Federico Corvi, SriniVas R. Sadda & Felipe A. Medeiros. (2023) Endpoints for clinical trials in ophthalmology. Progress in Retinal and Eye Research, pages 101160.
Crossref
Daiheon Lee, Gijung Kwak, Thomas V. Johnson & Jung Soo Suk. (2022) Formulation and Evaluation of Polymer‐Based Nanoparticles for Intravitreal Gene‐Delivery Applications. Current Protocols 2:12.
Crossref
Mahtab Farahbakhsh, Elaine J Anderson, Roni O Maimon-Mor, Andy Rider, John A Greenwood, Nashila Hirji, Serena Zaman, Pete R Jones, D Samuel Schwarzkopf, Geraint Rees, Michel Michaelides & Tessa M Dekker. (2022) A demonstration of cone function plasticity after gene therapy in achromatopsia. Brain 145:11, pages 3803-3815.
Crossref
Irene Vázquez-Domínguez, Lonneke Duijkers, Zeinab Fadaie, Eef C. W. Alaerds, Merel A. Post, Edwin M. van Oosten, Luke O’Gorman, Michael Kwint, Louet Koolen, Anita D. M. Hoogendoorn, Hester Y. Kroes, Christian Gilissen, Frans P. M. Cremers, Rob W. J. Collin, Susanne Roosing & Alejandro Garanto. (2022) The Predicted Splicing Variant c.11+5G>A in RPE65 Leads to a Reduction in mRNA Expression in a Cell-Specific Manner. Cells 11:22, pages 3640.
Crossref
Martina Kropp, Nina Harmening, Thais Bascuas, Sandra Johnen, Eline De Clerck, Verónica Fernández, Mattia Ronchetti, Ruggero Cadossi, Cristina Zanini, Daniel Scherman, Zoltán Ivics, Corinne Marie, Zsuzsanna Izsvák & Gabriele Thumann. (2022) GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration. Biomedicines 10:11, pages 2777.
Crossref
Susie Suh, Elliot H. Choi, Aditya Raguram, David R. Liu & Krzysztof Palczewski. (2022) Precision genome editing in the eye. Proceedings of the National Academy of Sciences 119:39.
Crossref
Neslihan Sinim Kahraman, Ayşe Öner, Yusuf Özkul & Munis Dündar. (2022) Frequency of <i>RPE65</i> Gene Mutation in Patients with Hereditary Retinal Dystrophy. Turkish Journal of Ophthalmology 52:4, pages 270-275.
Crossref
Xiufang Pan, Yongping Yue, Maria Boftsi, Lakmini P. Wasala, Ngoc Tam Tran, Keqing Zhang, David J. Pintel, Phillip W. L. Tai & Dongsheng Duan. (2021) Rational engineering of a functional CpG-free ITR for AAV gene therapy. Gene Therapy 29:6, pages 333-345.
Crossref
Jay Jiyong Kwak, Hae Rang Kim & Suk Ho Byeon. (2022) Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa. Yonsei Medical Journal 63:7, pages 701.
Crossref
Najam A. Sharif. 2022. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics 309 316 .
Alexander R. Harris & Frederic Gilbert. (2021) Restoring vision using optogenetics without being blind to the risks. Graefe's Archive for Clinical and Experimental Ophthalmology 260:1, pages 41-45.
Crossref
A. Daruich, C. Cotteret, S. Cisternino, M.P. Robert & D. Bremond-Gignac. (2021) Voretigene Neparvovec challenges in clinical practice. Journal Français d'Ophtalmologie 44:10, pages 1481-1483.
Crossref
Andrea Sodi, Sandro Banfi, Francesco Testa, Michele Della Corte, Ilaria Passerini, Elisabetta Pelo, Settimio Rossi & Francesca Simonelli. (2021) RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy. Orphanet Journal of Rare Diseases 16:1.
Crossref
Ivana Trapani, Patrizia Tornabene & Alberto Auricchio. (2020) Large gene delivery to the retina with AAV vectors: are we there yet?. Gene Therapy 28:5, pages 220-222.
Crossref
Szilárd Kiss, Kristina Oresic Bender, Ruslan N. Grishanin, Kelly M. Hanna, Julio D. Nieves, Pallavi Sharma, Aivan T. Nguyen, Romeo J. Rosario, Judith S. Greengard, Claire M. Gelfman & Mehdi Gasmi. (2021) Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates. Translational Vision Science & Technology 10:1, pages 34.
Crossref
Ashley E. Neiweem, Thomas A. Ciulla & Seenu M. Hariprasad. (2021) Genetic Testing Prevalence, Guidelines, and Pitfalls in Large, University-Based Medical Systems. Ophthalmic Surgery, Lasers and Imaging Retina 52:1, pages 6-10.
Crossref
David A. Camp, Paulo Falabella & Thomas A. Ciulla. (2021) RPE65 Mutation-associated Inherited Retinal Disease and Gene Therapies. International Ophthalmology Clinics 61:4, pages 125-132.
Crossref
Aumer Shughoury, Thomas A. Ciulla, Benjamin Bakall, Mark E. Pennesi, Szilárd Kiss & Emmett T. Cunningham. (2021) Genes and Gene Therapy in Inherited Retinal Disease. International Ophthalmology Clinics 61:4, pages 3-45.
Crossref
Thomas Ciulla, Mark E. Pennesi, Szilárd Kiss & Emmett T. Cunningham. (2021) DNA- and RNA-based Gene Therapies in Ophthalmology. International Ophthalmology Clinics 61:3, pages 3-16.
Crossref
Nicholas Spittal. 2021. Rare Disease Drug Development. Rare Disease Drug Development 213 232 .
Maria Carmo-Fonseca. 2021. Precision Medicine in Stroke. Precision Medicine in Stroke 9 19 .
Philip J. BrooksElizabeth A. Ottinger, Deanna PorteroRicha Madan Lomash, Asaf Alimardanov, Pramod Terse, Xin Xu, Randy J. ChandlerJanelle Geist HausermanEric EspositoCarsten G. BönnemannCharles P. VendittiChristopher P. AustinAnne PariserDonald C. Lo, Gilberto V. Averion, Krishna Balakrishnan, Steven J. Burden, Eggerton Campbell, Catherine Chen, Claire Driscoll, Oksana Dukhanina, Susan Ferry, A. Reghan Foley, Lina Li, Irini Manoli, Christopher Mendoza, Julien Oury, Forbes D. Porter, Lili Portilla, Dimah Saade, Oleg A. Shchelochkov, Jennifer L. Sloan, Joshua Todd, London Toney, Carol Van Ryzin, Sury Vepa, Erik Wagner & Amy Wang. (2020) The Platform Vector Gene Therapies Project: Increasing the Efficiency of Adeno-Associated Virus Gene Therapy Clinical Trial Startup. Human Gene Therapy 31:19-20, pages 1034-1042.
Crossref
Da Meng, Sara D. Ragi & Stephen H. Tsang. (2020) Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. Molecular Therapy 28:10, pages 2139-2149.
Crossref
Kari Branham, Dana Schlegel, Abigail T. Fahim & K. Thiran Jayasundera. (2020) Genetic testing for inherited retinal degenerations: Triumphs and tribulations. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 184:3, pages 571-577.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.